查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1808487

神經退化藥物市場按類型、藥物類別、劑型、作用機制、治療方法、適應症、患者人口統計、銷售管道和最終用戶分類 - 2025-2030 年全球預測

Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年神經退化藥物市值將達444.9億美元，2025年成長至477.9億美元，複合年成長率為7.66%，2030年將達693億美元。

主要市場統計數據
基準年2024年 444.9億美元
預計2025年 477.9億美元
預測年份 2030 693億美元
複合年成長率（%） 7.66%

在前所未有的科學和政策動盪中揭示神經退化性疾病藥物研究和市場開發的基本原理

全球人口老化和多因素疾病機制導致神經退化性疾病的發生，對現代醫療保健構成了最複雜的挑戰之一。阿茲海默症、帕金森氏症、肌萎縮側索硬化症和多發性硬化症等疾病正推動著人們對能夠同時緩解症狀和潛在疾病進展的新型治療策略的需求。在這種迫切需求的驅動下，分子生物學、基因編輯和生物標記發現領域的突破正在重新定義藥物開發的典範。

透過突破性發現和監管變化追蹤神經退化疾病治療的轉變

由於科學進步和監管環境的不斷演變，神經退化醫學領域正在發生重大變化。精準醫療方法已經確定了新的分子標靶，從而能夠開發出減緩或阻止疾病進展的治療方法。基因治療、單株抗體和小分子調變器的創新正在提供前所未有的干涉途徑。同時，主要市場的監管機構正在引入適應性許可製度和有條件核准，以應對患有衰弱性神經系統疾病的患者迫切而未得到滿足的需求。

檢驗2025 年美國關稅對神經退化藥物供應鏈、定價結構和國際競爭力的累積影響

2025年美國關稅的實施將為神經退化疾病供應鏈帶來新的複雜性，對原料藥和成品均產生影響。依賴跨境採購的製造商面臨不斷上升的投入成本，導致價格壓力波及整個分銷網路。為此，企業開始重組供應鏈，探索替代採購途徑，並強化國內製造能力，以緩解關稅帶來的成本上漲。

關鍵市場細分洞察，有助於根據藥物類別、給藥方式和患者概況進行策略性定位

細緻入微地了解市場區隔對於制定神經退化藥物領域的研發投資和商業化策略至關重要。按藥物類型分類，品牌藥和學名藥的區別體現了不同的價值提案，創新品牌藥價格昂貴，而學名藥具有成本效益。依藥物類別分類，膽鹼酯酶抑制劑（如多奈哌齊、吡斯的明和Rivastigmine的明）在支持認知功能方面發揮著重要作用，而脫羧酶抑制劑（如芐絲肼、碳度巴和甲基多巴）則與多巴胺促效劑（如阿樸嗎啡嗎啡、卡麥角林、Pramipexole和rotigotine相輔成。免疫調節劑透過針對緩解疾病途徑，為治療開闢了新的方向。

揭示影響神經退化藥物採用模式和重點區域投資重點的關鍵區域動態

區域動態顯著影響著神經退化藥物的採用和投資軌跡。在美洲，強大的研究基礎設施和大量的公共和私人資金加速了尖端療法的開發，而完善的報銷框架則支持了商業性擴充性。該地區的市場參與企業利用先進的臨床試驗網路和上市後調查計畫來檢驗真實世界結果並加強市場准入。

重點介紹推動神經退化性疾病治療市場創新夥伴關係和競爭策略的產業領導者

在神經退化醫學領域，一些機構以其開創性的研發和商業化方法脫穎而出。這些行業領導者正在利用多學科合作，將學術見解與內部研發能力相結合，以加速候選藥物的篩選和臨床前測試。他們與生物技術公司和技術供應商建立策略聯盟，利用先進的分析技術和人工智慧來最佳化試驗設計和患者招募策略。

為行業領導者制定可行的策略建議，以因應不斷變化的市場和監管環境

要想在充滿活力的神經退化醫學領域取得成功，產業領導者必須採取多管齊下的策略方針。首先，優先投資基因療法、生物標記主導平台和數位健康整合等前沿舉措項目，可以讓企業處於創新前沿。其次，透過建立區域製造中心和達成替代採購協議來實現供應鏈多元化，可以降低關稅波動和地緣政治變化帶來的財務和營運風險。

詳細了解我們強大的調查方法，它結合了多方面的資料來源、專家分析和嚴格的檢驗過程。

本研究採用全面的調查方法，旨在提供切實可行的見解和可靠的分析。本研究以廣泛的二手資料研究為基礎，涵蓋同行評審期刊、監管備案文件和臨床試驗資料庫，旨在了解神經退化性疾病藥物研發的現狀。此外，本研究也對神經科、藥理學家和患者權益代表等關鍵意見領袖進行了初步訪談，從而對治療需求和應用趨勢提供了細緻入微的觀點。

整合核心見解和策略意義，指導神經退化性疾病領域的相關人員決策

綜上所述，本分析結果凸顯了神經退化性疾病藥物研發的變革軌跡。分子標靶和生物標記識別領域的科學突破，與加速患者用藥可及性的監管創新相輔相成。同時，不斷變化的關稅政策和供應鏈動態需要企業制定適應性的商業策略，以維持成本效益和全球競爭力。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章市場動態

  • 開發用於神經退化綜合治療的多標靶藥物
  • 基因治療在治療遺傳性神經退化性疾病的進展
  • 人們對重新利用現有藥物治療神經退化性疾病的興趣日益濃厚
  • 臨床試驗進展揭示了新型神經退化疾病治療的療效
  • 將人工智慧和機器學習融入神經退化性疾病藥物研發
  • 擴展針對神經發炎路徑的小分子藥物
  • 免疫治療方法在神經退化性疾病治療的影響日益擴大
  • 神經退化疾病藥物血腦障壁穿透技術進展
  • 生物標記在神經退化性疾病個人化治療發展中的作用
  • 針對神經退化性疾病中蛋白質聚集的創新藥物製劑

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章神經退化藥物市場（按類型）

  • 品牌
  • 學名藥

第9章神經退化藥物市場（依藥物類別）

  • 膽鹼酯酶抑制劑
    • 多奈哌齊
    • 吡啶斯的明
    • Rivastigmine
  • 脫羧酶抑制劑
    • 芐絲肼
    • 碳度巴
    • 甲基多巴
  • 促效劑
    • 阿撲嗎啡
    • 卡麥角林
    • Pramipexole
    • rotigotine
  • 免疫調節藥物

第 10 章神經退化藥物市場（按劑型）

  • 注射
  • 口服
  • 經皮吸收貼片

第 11 章神經退化藥物市場（依作用機制）

  • 離子通道調變器
    • 鉀通道調變器
    • 鈉通道調變器
  • 突觸調變器

第 12 章神經退化藥物市場（依治療方法）

  • 神經保護
    • 抗發炎劑
    • 抗氧化劑
  • 預防性治療
  • 症狀治療

第13章神經退化藥物市場（依適應症）

  • 阿茲海默症
  • 肌萎縮側索硬化症（ALS）
  • 多發性硬化症
    • 原發性進展型
    • 復發緩解型
  • 帕金森氏症

第 14 章神經退化藥物市場（依病患人口統計）

  • 成人
  • 老年人
  • 孩子們

第 15 章神經退化藥物市場依銷售管道

  • 離線
    • 醫院藥房
    • 零售藥局
  • 線上

第 16 章神經退化藥物市場（依最終使用者）

  • 診所
  • 受託研究機構
  • 醫院
  • 研究所

17. 美國神經退化疾病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

18. 歐洲、中東和非洲神經退化藥物市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

19. 亞太神經神經退化藥物市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第20章 競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • AbbVie Inc.
    • ACADIA Pharmaceuticals Inc.
    • Alpha Cognition Inc.
    • Amneal Pharmaceuticals, Inc.
    • Aquinnah Pharmaceuticals Inc.
    • Asceneuron SA
    • AstraZeneca PLC
    • AZTherapies, Inc.
    • Bausch Health Companies Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • Denali Therapeutics Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline PLC
    • H. Lundbeck A/S
    • Johnson & Johnson Services, Inc.
    • Kyowa Kirin International plc
    • Lupin Limited
    • Merck & Co., Inc.
    • Novartis AG
    • Orion Corporation by Smiths Group plc
    • Pfizer, Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
    • UCB SA

第21章 研究人工智慧

第22章 研究統計

第23章 研究聯絡人

第24章 研究報導

第25章 附錄

Product Code: MRR-C002B1C996F9

The Neurodegenerative Drugs Market was valued at USD 44.49 billion in 2024 and is projected to grow to USD 47.79 billion in 2025, with a CAGR of 7.66%, reaching USD 69.30 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 44.49 billion
Estimated Year [2025] USD 47.79 billion
Forecast Year [2030] USD 69.30 billion
CAGR (%) 7.66%

Unveiling the Foundations of Neurodegenerative Drug Research and Market Evolution Amidst Unprecedented Scientific and Policy Disruptions

Neurodegenerative disorders present one of the most complex challenges to modern healthcare, driven by an aging global population and multifactorial disease mechanisms. Conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis have propelled the need for novel therapeutic strategies that address both symptoms and underlying disease progression. Amid this imperative, breakthroughs in molecular biology, gene editing, and biomarker discovery are redefining the paradigms of drug development.

At the same time, regulatory landscapes are evolving to accommodate accelerated approval pathways and expanded access frameworks, creating a more flexible environment for innovators to bring therapies to patients in need. The integration of real-world evidence and digital health platforms has enhanced clinical trial design, enabling more precise patient stratification and adaptive study protocols. Collaborative models between academic institutions, biotechnology startups, and established pharmaceutical companies are further accelerating the translation of preclinical insights into clinical candidates.

Looking ahead, the focus is shifting towards holistic approaches that combine neuroprotection, immunomodulation, and synaptic support. Stakeholders are increasingly evaluating combination therapies and leveraging artificial intelligence to optimize drug discovery pipelines. This introduction sets the stage for an in-depth exploration of the transformative shifts, policy impacts, segmentation nuances, regional dynamics, and strategic imperatives that define the future of neurodegenerative drug development.

Tracing the Transformative Shifts in Neurodegenerative Therapy Landscape Fueled by Breakthrough Discoveries and Regulatory Overhauls

The neurodegenerative drug landscape is undergoing a profound metamorphosis, catalyzed by converging scientific advances and shifts in regulatory philosophy. Precision medicine initiatives have identified novel molecular targets, enabling the development of therapies that may slow or halt disease progression. Innovations in gene therapy, monoclonal antibodies, and small molecule modulators are offering unprecedented avenues for intervention. Concurrently, regulatory bodies across major markets have introduced adaptive licensing schemes and conditional approvals, recognizing the urgent unmet needs of patients affected by debilitating neurological conditions.

In parallel, technological advancements in imaging, fluid biomarkers, and omics analytics are refining diagnostic criteria and enabling earlier intervention. Digital therapeutics and remote monitoring devices are enhancing patient engagement and supporting data-driven decision making. This ecosystem of innovation has fostered strategic alliances, where biopharma companies collaborate with technology firms to co-develop integrated solutions that extend beyond traditional pharmacotherapy.

As a result, clinical trial paradigms are evolving towards decentralized models and master protocols, reducing time to market and improving the efficiency of patient recruitment. These transformative shifts not only accelerate access to cutting-edge treatments but also redefine competitive dynamics, compelling stakeholders to reevaluate their pipelines, partnerships, and go-to-market strategies in light of an increasingly agile and patient-centric environment.

Examining the Cumulative Effects of 2025 US Tariffs on Neurodegenerative Drug Supply Chains, Pricing Structures, and Global Competitiveness

The implementation of United States tariffs in 2025 has introduced a new layer of complexity to the neurodegenerative drug supply chain, impacting both active pharmaceutical ingredients and finished formulations. Manufacturers reliant on cross-border sourcing have encountered elevated input costs, leading to pricing pressures that reverberate throughout distribution networks. In response, companies have initiated supply chain realignment efforts, exploring alternative procurement corridors and reinforcing domestic manufacturing capabilities to mitigate tariff-driven cost escalations.

These developments have altered global competitiveness, particularly for firms exporting to or from regions with disparate tariff frameworks. Negotiations with contract manufacturing organizations and distribution partners now emphasize risk-sharing arrangements and flexible contract terms to absorb additional financial burdens. At the same time, pricing committees and reimbursement agencies are closely monitoring tariff-induced cost fluctuations, requiring more transparent cost-justification frameworks.

Looking forward, industry players are increasingly adopting dynamic pricing strategies and leveraging trade agreements to optimize cross-border operations. Collaboration with regulatory authorities and trade bodies has become essential to navigate evolving tariff schedules and to advocate for policy adjustments that recognize the critical nature of neurodegenerative therapies. This analysis highlights the cumulative impact of tariff policies on market dynamics, underscoring the need for adaptive supply chain resilience and strategic cost management.

Illuminating Critical Market Segmentation Insights That Inform Strategic Positioning Across Drug Types Classes Administration Modes and Patient Profiles

A nuanced understanding of market segmentation is essential for tailoring R&D investments and commercialization strategies within the neurodegenerative drug space. When examined by type, the distinction between branded and generic therapies reveals divergent value propositions, with innovative brand portfolios commanding premium pricing while generics offer cost-effective access. Within drug classes, cholinesterase inhibitors such as donepezil, pyridostigmine and rivastigmine play a key role in cognitive support, whereas decarboxylase inhibitors like benserazide, carbidopa and methyldopa complement dopamine agonists including apomorphine, cabergoline, pramipexole and rotigotine. Immunomodulators add another dimension by targeting disease-modifying pathways.

Mode of administration further segments the market into injectable, oral, and transdermal patch formats, influencing patient adherence and route-specific efficacy. Mechanisms of action are delineated between ion channel modulators-spanning potassium and sodium channel regulators-and synaptic modulators that address neurotransmitter dynamics. Therapeutic approaches divide into neuroprotection, preventive treatment and symptomatic relief, with neuroprotective strategies encompassing anti-inflammatory agents and antioxidants. Indication-based segmentation highlights applications in Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis-with primary progressive and relapsing-remitting subtypes-and Parkinson's disease. Patient demographics reveal distinct usage patterns across adult, geriatric and pediatric cohorts, while sales channels, whether offline through hospital and retail pharmacies or online platforms, shape distribution dynamics. Finally, end users spanning clinics, contract research organizations, hospitals and research institutes drive demand based on clinical and investigational needs.

Together, these segmentation insights empower leaders to align product development, pricing models and market entry strategies with the diverse needs of stakeholders across the value chain.

Uncovering Key Regional Dynamics Shaping Neurodegenerative Drug Adoption Patterns and Investment Priorities Across Major Geographies

Regional dynamics exert a profound influence on the trajectory of neurodegenerative drug adoption and investment. In the Americas, robust research infrastructure and significant public and private funding have accelerated the development of cutting-edge therapeutics, while established reimbursement frameworks support commercial scalability. Market participants in this region are leveraging advanced clinical trial networks and post-market surveillance programs to validate real-world outcomes and reinforce market access.

Across Europe, the Middle East and Africa, heterogeneous regulatory environments present both challenges and opportunities. Countries with streamlined approval pathways and patient access schemes foster innovation, whereas regions with constrained healthcare budgets demand tailored cost-benefit justifications. Geographic nuances in disease prevalence, healthcare spending and care delivery models further guide strategic partnerships and localized R&D initiatives.

The Asia-Pacific region is characterized by rapid urbanization, rising healthcare expenditure and expanding clinical trial capacity. A growing middle-class population and favorable policy incentives are attracting global players to establish manufacturing hubs and research centers. Local regulatory bodies are increasingly harmonizing guidelines with international standards, promoting faster market entry for novel therapies. Understanding these distinct regional landscapes enables stakeholders to optimize portfolio allocation, forge strategic alliances and adapt commercialization strategies to the unique parameters of each geography.

Highlighting Leading Industry Players Driving Innovation Partnerships and Competitive Strategies in the Neurodegenerative Drug Market

Within the neurodegenerative drug arena, certain organizations stand out for their pioneering approaches to research, development and commercialization. These industry leaders leverage cross-disciplinary collaborations, integrating academic insights with in-house R&D capabilities to accelerate candidate selection and preclinical validation. Strategic alliances with biotechnology firms and technology providers have allowed them to harness advanced analytics and artificial intelligence, optimizing trial design and patient recruitment strategies.

Furthermore, these companies are redefining the competitive landscape through targeted acquisitions and licensing agreements, expanding their pipelines to include both disease-modifying and symptomatic treatments. Their focus on specialty formulations and novel delivery systems has improved therapeutic outcomes and patient adherence. In parallel, they maintain robust portfolios of biomarkers and companion diagnostics, enabling more precise patient stratification and personalized care models.

To sustain their market leadership, these players continually strengthen their global footprint. They invest in manufacturing capacity, secure strategic partnerships for distribution, and engage proactively with regulatory agencies to navigate complex approval pathways. By combining financial resilience with scientific excellence, these companies set the benchmark for innovation, operational efficiency and commercial success in the neurodegenerative drug sector.

Formulating Actionable Strategic Recommendations for Industry Leaders to Navigate Evolving Market Landscapes and Regulatory Environments

To thrive in the dynamic field of neurodegenerative therapeutics, industry leaders must adopt a multi-faceted strategic approach. First, prioritizing investment in cutting-edge R&D initiatives, including gene therapies, biomarker-driven platforms and digital health integrations, will position organizations at the forefront of innovation. Second, diversifying supply chains by establishing regional manufacturing hubs and securing alternative sourcing agreements can mitigate the financial and operational risks associated with tariff fluctuations and geopolitical shifts.

In addition, fostering collaborative ecosystems with technology partners, academic centers and patient advocacy groups will accelerate translational research and enhance stakeholder engagement. This collaborative ethos should extend to regulatory strategy, where early dialogue with health authorities can streamline approval pathways and align clinical trial endpoints with payer expectations. Moreover, implementing patient-centric programs that support adherence, education and long-term outcomes will strengthen market access and underpin value-based care models.

Finally, organizations must refine their commercial strategies through dynamic pricing frameworks and adaptive go-to-market plans that reflect regional nuances and evolving reimbursement landscapes. By executing these recommendations, industry leaders can navigate uncertainties, capitalize on emerging opportunities and deliver meaningful therapeutic advances to patients living with neurodegenerative conditions.

Detailing a Robust Research Methodology Integrating Multidimensional Data Sources Expert Analyses and Rigorous Validation Processes

This study employs a comprehensive research methodology designed to deliver actionable insights and reliable analysis. The foundation rests on extensive secondary research, incorporating peer-reviewed journals, regulatory filings and clinical trial databases to map the current state of neurodegenerative drug development. Building on this, primary research engagements with key opinion leaders, including neurologists, pharmacologists and patient advocacy representatives, provide nuanced perspectives on therapeutic needs and adoption trends.

Quantitative analysis leverages real-world evidence and proprietary datasets, employing statistical validation techniques to ensure data integrity and reproducibility. Qualitative insights from expert interviews and roundtable discussions enrich the quantitative findings, identifying emerging themes and potential inflection points. The methodology also includes a thorough review of policy frameworks, trade agreements and tariff schedules to assess regulatory impacts on supply chains and pricing structures.

Data triangulation and scenario analysis further validate the robustness of conclusions, while peer benchmarking and portfolio mapping contextualize competitive positioning. This multi-dimensional approach ensures that the study's conclusions are grounded in empirical evidence, expert judgment and strategic foresight, equipping stakeholders with the insights needed to make informed decisions in the neurodegenerative drug domain.

Synthesizing Core Findings and Strategic Implications to Guide Stakeholder Decisions in the Neurodegenerative Drug Domain

The synthesis of this analysis underscores the transformative trajectories reshaping neurodegenerative drug development. Scientific breakthroughs in molecular targeting and biomarker identification are complemented by regulatory innovations that accelerate patient access. At the same time, evolving tariff policies and supply chain dynamics necessitate adaptive operational strategies to maintain cost efficiency and global competitiveness.

Segmenting the market by drug type, class, administration mode, mechanism of action, therapeutic approach, indication, demographics, sales channel and end user reveals the nuanced pathways to value creation. Regionally tailored strategies highlight the importance of understanding local regulatory frameworks, reimbursement models and healthcare infrastructure. Leading industry players demonstrate the competitive advantages of strategic partnerships, pipeline diversification and technology integration.

Actionable recommendations emphasize the need for investment in advanced R&D, supply chain resilience, collaborative ecosystems, regulatory engagement and patient-centric care models. Rigorous methodological validation ensures that these insights are not only evidence-based but also forward-looking, preparing stakeholders to navigate future uncertainties. This conclusion ties together the study's core findings, offering a clear roadmap for decision-makers seeking to capitalize on the opportunities presented by the evolving landscape of neurodegenerative therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Development of multi-target drugs for comprehensive neurodegeneration treatment
  • 5.2. Advancements in gene therapy for treatment of inherited neurodegenerative disorders
  • 5.3. Increasing focus on repurposing existing drugs for neurodegenerative disease applications
  • 5.4. Clinical trial breakthroughs revealing efficacy of novel neurodegenerative therapies
  • 5.5. Integration of AI and machine learning in neurodegenerative drug discovery and development
  • 5.6. Expansion of small molecule drugs targeting neuroinflammation pathways
  • 5.7. Growing impact of immunotherapy approaches in neurodegenerative disease management
  • 5.8. Progress in blood-brain barrier penetration technologies for neurodegenerative drugs
  • 5.9. Emerging role of biomarkers in personalized neurodegenerative drug development
  • 5.10. Innovative drug formulations targeting protein aggregation in neurodegenerative diseases

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Neurodegenerative Drugs Market, by Type

  • 8.1. Introduction
  • 8.2. Branded
  • 8.3. Generics

9. Neurodegenerative Drugs Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Cholinesterase Inhibitors
    • 9.2.1. Donepezil
    • 9.2.2. Pyridostigmine
    • 9.2.3. Rivastigmine
  • 9.3. Decarboxylase Inhibitors
    • 9.3.1. Benserazide
    • 9.3.2. Carbidopa
    • 9.3.3. Methyldopa
  • 9.4. Dopamine Agonist
    • 9.4.1. Apomorphine
    • 9.4.2. Cabergoline
    • 9.4.3. Pramipexole
    • 9.4.4. Rotigotine
  • 9.5. Immunomodulators

10. Neurodegenerative Drugs Market, by Mode Of Administration

  • 10.1. Introduction
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Transdermal Patch

11. Neurodegenerative Drugs Market, by Mechanism Of Action

  • 11.1. Introduction
  • 11.2. Ion Channel Modulators
    • 11.2.1. Potassium Channel Modulators
    • 11.2.2. Sodium Channel Modulators
  • 11.3. Synaptic Modulators

12. Neurodegenerative Drugs Market, by Therapeutic Approach

  • 12.1. Introduction
  • 12.2. Neuroprotection
    • 12.2.1. Anti-Inflammatory Agents
    • 12.2.2. Antioxidants
  • 12.3. Preventive Treatment
  • 12.4. Symptomatic Treatment

13. Neurodegenerative Drugs Market, by Indication

  • 13.1. Introduction
  • 13.2. Alzheimer's Disease
  • 13.3. Amyotrophic Lateral Sclerosis (ALS)
  • 13.4. Multiple Sclerosis
    • 13.4.1. Primary Progressive
    • 13.4.2. Relapsing-Remitting
  • 13.5. Parkinson's Disease

14. Neurodegenerative Drugs Market, by Patient Demographics

  • 14.1. Introduction
  • 14.2. Adult
  • 14.3. Geriatric
  • 14.4. Pediatric

15. Neurodegenerative Drugs Market, by Sales Channel

  • 15.1. Introduction
  • 15.2. Offline
    • 15.2.1. Hospitals Pharmacies
    • 15.2.2. Retail Pharmacies
  • 15.3. Online

16. Neurodegenerative Drugs Market, by End User

  • 16.1. Introduction
  • 16.2. Clinics
  • 16.3. Contract Research Organizations
  • 16.4. Hospitals
  • 16.5. Research Institutes

17. Americas Neurodegenerative Drugs Market

  • 17.1. Introduction
  • 17.2. United States
  • 17.3. Canada
  • 17.4. Mexico
  • 17.5. Brazil
  • 17.6. Argentina

18. Europe, Middle East & Africa Neurodegenerative Drugs Market

  • 18.1. Introduction
  • 18.2. United Kingdom
  • 18.3. Germany
  • 18.4. France
  • 18.5. Russia
  • 18.6. Italy
  • 18.7. Spain
  • 18.8. United Arab Emirates
  • 18.9. Saudi Arabia
  • 18.10. South Africa
  • 18.11. Denmark
  • 18.12. Netherlands
  • 18.13. Qatar
  • 18.14. Finland
  • 18.15. Sweden
  • 18.16. Nigeria
  • 18.17. Egypt
  • 18.18. Turkey
  • 18.19. Israel
  • 18.20. Norway
  • 18.21. Poland
  • 18.22. Switzerland

19. Asia-Pacific Neurodegenerative Drugs Market

  • 19.1. Introduction
  • 19.2. China
  • 19.3. India
  • 19.4. Japan
  • 19.5. Australia
  • 19.6. South Korea
  • 19.7. Indonesia
  • 19.8. Thailand
  • 19.9. Philippines
  • 19.10. Malaysia
  • 19.11. Singapore
  • 19.12. Vietnam
  • 19.13. Taiwan

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. Abbott Laboratories
    • 20.3.2. AbbVie Inc.
    • 20.3.3. ACADIA Pharmaceuticals Inc.
    • 20.3.4. Alpha Cognition Inc.
    • 20.3.5. Amneal Pharmaceuticals, Inc.
    • 20.3.6. Aquinnah Pharmaceuticals Inc.
    • 20.3.7. Asceneuron SA
    • 20.3.8. AstraZeneca PLC
    • 20.3.9. AZTherapies, Inc.
    • 20.3.10. Bausch Health Companies Inc.
    • 20.3.11. Biogen Inc.
    • 20.3.12. Boehringer Ingelheim International GmbH
    • 20.3.13. Denali Therapeutics Inc.
    • 20.3.14. Eli Lilly and Company
    • 20.3.15. GlaxoSmithKline PLC
    • 20.3.16. H. Lundbeck A/S
    • 20.3.17. Johnson & Johnson Services, Inc.
    • 20.3.18. Kyowa Kirin International plc
    • 20.3.19. Lupin Limited
    • 20.3.20. Merck & Co., Inc.
    • 20.3.21. Novartis AG
    • 20.3.22. Orion Corporation by Smiths Group plc
    • 20.3.23. Pfizer, Inc.
    • 20.3.24. Sanofi SA
    • 20.3.25. Takeda Pharmaceutical Company Limited
    • 20.3.26. Theravance Biopharma
    • 20.3.27. UCB S.A.

21. ResearchAI

22. ResearchStatistics

23. ResearchContacts

24. ResearchArticles

25. Appendix

LIST OF FIGURES

  • FIGURE 1. NEURODEGENERATIVE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
  • FIGURE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 26. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 30. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 31. NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 33. NEURODEGENERATIVE DRUGS MARKET: RESEARCHAI
  • FIGURE 34. NEURODEGENERATIVE DRUGS MARKET: RESEARCHSTATISTICS
  • FIGURE 35. NEURODEGENERATIVE DRUGS MARKET: RESEARCHCONTACTS
  • FIGURE 36. NEURODEGENERATIVE DRUGS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. NEURODEGENERATIVE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 141. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 143. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 145. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 147. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 153. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 155. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 157. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 193. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 199. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 203. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 204. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 205. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 206. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 207. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 208. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 209. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 211. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 212. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 213. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 214. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 215. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 216. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 217. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 218. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 219. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 221. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 223. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 225. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 227. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 229. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 231. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 235. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 237. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 238. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 239. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 240. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 241. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 243. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 244. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 245. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 246. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 247. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 248. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 249. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 251. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 253. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 255. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 256. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 257. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 259. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 261. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 263. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 267. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 268. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 269. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 270. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 271. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 272. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 273. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 275. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 276. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 277. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 278. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 279. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 281. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 282. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 283. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 285. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 287. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 288. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 289. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 291. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 292. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 293. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 295. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 299. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 300. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 301. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 302. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 303. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 304. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 305. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 307. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 308. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 309. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 310. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 311. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 312. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 313. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 314. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 315. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 317. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 318. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS